Accretion Nutraveda Limited
Bookbuilding IPO · BSE
- Price band
- ₹122 - ₹129
- Lot size
- 1,000 shares
- Issue amount
- ₹24.77 cr
- Total subscription
- 1.91×
- Opens
- 28 Jan 2026
- Closes
- 30 Jan 2026
- Allotment
- 2 Feb 2026
- Listing
- 4 Feb 2026
Offer at a glance
Issue overview
- Issue size
- 19,20,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,22,000
- Fresh issue
- ₹24.77 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,29,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 53,20,000
- Shares after issue
- 72,40,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,000 | ₹2,58,000 |
| sHNI | 3 | 3,000 | ₹3,87,000 |
| bHNI | 8 | 8,000 | ₹10,32,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 30 Jan 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 2 |
| NIB | 0 | 107 |
| RETAIL | 320 | 702 |
| HNIs(10L +) | 61 | 45 |
| HNIs (2-10L) | 31 | 62 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 4.7 | 4.73 |
| FIIs | 0 | 4.67 |
| Others | 0 | 0.06 |
| RETAIL | 8.26 | 18.11 |
| HNIs 2+ | 1.19 | 2.76 |
| HNIs 10+ | 2.37 | 5.87 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Sep-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 4.73 | 7.19 | 2.28 |
| ROE | 68.54 | 81.22 | 121.94 |
| ROCE | 49.09 | 36.98 | 28.98 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 26.27 | 0 |
| POST IPO(PE) | 20.02 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Influx Healthtech Ltd | 46.99 | 226.00 | 10.00 | 38.98 | 11.1 | 4.81 |
| Walpar Nutritions Ltd | 3.3 | 45.90 | 10.00 | 17.05 | 6.24 | 1.06 |
| Accretion Nutraveda Limited | 26.27 | 129.00 | 10.00 | 16.74 | 56.5 | 4.73 |
Company information
Company profile
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and nutraceutical products across multiple dosage forms such as tablets, capsules, oral liquids, powders, oils, and external applications including balms, creams, and gels, operating as a Contract Development and Manufacturing Organization (CDMO) for both domestic and international markets including Sri Lanka, Singapore, and the USA. The company blends classical Ayurvedic formulations with modern nutraceutical science to address wellness segments such as liver care, women’s health, bone and joint health, cognitive support, and respiratory health, with its revenue primarily driven by domestic sales and merchant exports on a loan license basis, along with a growing contribution from direct exports. It operates a 10,763 sq. ft. manufacturing facility in Gujarat equipped with modern infrastructure, multiple air handling units, segregated processing areas, and quality control systems, and holds certifications including GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, Halal, and FSSAI.
Strengths
- Experienced Management Team: Promoters and leaders with strong expertise in Ayurvedic and nutraceutical manufacturing.
- Diverse Product Portfolio: Offers products across various therapeutic and wellness segments.
- Quality & Compliance Focus: Backed by multiple global certifications ensuring high standards.
Risk factors
- Manufacturing Operational Risk: Equipment failures, accidents, or natural events may disrupt production.
- Regulatory & Compliance Risk: Past filing discrepancies may lead to regulatory issues.
- Customer Concentration Risk: Dependence on a few customers exposes revenue to potential volatility.
Promoters
Mr. Mayur Popatlal Sojitra
Mr. Ankurkumar Shantilal Patel
Mr. Paraskumar Vinubhai Parmar
Mr. Hardik Mukundbhai Prajapati
Mr. Harshad Nanubhai Rathod
Mr. Vivek Ashok Kumar Patel
Registrar & documents
Lead manager
Sobhagya Capital Options Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
27 Xcelon Industrial Park-1 Vasna-Chacharwadi, TaSanand, Ahmedabad, Gujarat, 382213
+91- 9904366177
[email protected]Company website ↗Frequently Asked Questions
What is Accretion Nutraveda IPO GMP today?
As of today, Accretion Nutraveda IPO Grey Market Premium (GMP) is reported at +₹27 per share. Based on the upper price band of ₹129, the estimated listing price is ₹156 (+20.9% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Accretion Nutraveda IPO?
The minimum bid lot size for Accretion Nutraveda IPO is 1,000 shares. At the cut-off price of ₹129 per share, retail investors need a minimum application amount of ₹1,29,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Accretion Nutraveda IPO allotment status be announced?
The allotment status for Accretion Nutraveda IPO is scheduled to be finalized on 2 Feb 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Kfin Technologies Limited's official portal or via BSE/NSE allotment portals.
How can I check Accretion Nutraveda IPO allotment status online by PAN?
To check Accretion Nutraveda IPO allotment status: 1) Visit the registrar portal (Kfin Technologies Limited) or the BSE IPO allotment page. 2) Select 'Accretion Nutraveda Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.